Back to MGC Pharmaceuticals or All Oil Concentrates

Details provided are based upon best-known information made available to MedBud, please reconfirm with your pharmacy. This product was last updated:
MedBud typically only updates products when availability changes, or new information is provided. An availability status from several months ago can still be valid when a product remains in/out of stock, or has been discontinued.

Dosing Look-Up Table (Estimated)

0.01/g0.5/mg THC10/mg CBD
0.05/g2.5/mg THC50/mg CBD
0.1/g5/mg THC100/mg CBD
0.15/g7.5/mg THC150/mg CBD
0.2/g10/mg THC200/mg CBD
0.25/g12.5/mg THC250/mg CBD
0.3/g15/mg THC300/mg CBD
/gCalculate THCCalculate CBD

Please note values above are based on registered THC/CBD percentages, subject to ±10% allowed variance. Values provided are 'best case', losses to air during vaporisation or combustion will always occur.

Medication Details

Brand
Australia MGC Pharmaceuticals
Designation
CannEpil® T5:C100
Chemotype
Type II: THC/CBD Mix
Carrier Oil
Ionic Complex (Oil Free)
THC Potential Range (±10%)
4.5-5.5/mg
CBD Potential Range (±10%)
90-110/mg
Imported by
Australia MGC Pharmaceuticals

Stock Availability

We provide stock/pharmacy information only for use by medical cannabis patients, clinicians and pharmacists*.

Best-Known Status: Available

We try to ascertain stock status strictly based on the importer/distributor supplying pharmacies. Availability at individual pharmacies will differ.

*Cannabis is a controlled-substance and can only be legally dispensed upon submission of a valid prescription from a prescribing clinic, ordinarily listed.

Main Partner Pharmacy

Pharmacy Distributor

Dispensing Patient Pharmacies

Product DescriptionPatient Reviews

CannEpil® is a phyto medicine based on phytocannabinoids currently investigated for the treatment of refractory epilepsy. Produced from two proprietaries, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.

The first medicinal cannabis product eligible for patients in Ireland and fully covered under Ireland's Primary Care Reimbursement Service as part of the country's Medicinal Cannabis Access Programme (MCAP).

Available to prescribe in Australia and UK as an Investigational Medicinal Product through early patient access schemes.

MGC’s first pharmaceutical-grade product currently investigated for drug-resistant (refractory) epilepsy, which accounts for approximately 25% of the people diagnosed with epilepsy.

Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

Australia About MGC Pharmaceuticals Ltd

MGC Pharmaceuticals Logo

Changing lives with plant-based medicines. We are a bio-pharma company utilising the medical value of phytocannabinoids to provide relief to people suffering across the globe.

Founded in 2015, MGC Pharma aims to provide patients with the highest standard of phytomedicines in order to improve the quality of life for millions across the globe.

Our vision is to have a global impact on undertreated medical conditions and diseases, using the power of plant-based medicine in novel combinations by using technology to harness knowledge and science to achieve our “Nature to Medicine” strategy.

mgcpharma.co.uk

  Information provided is partially -sourced and may be outdated or otherwise incorrect. Please report any inaccuracies found by email.

NHS LogoFurther National Health-Service Information on Cannabis-Based Products for Medicinal Use (CBPMs)